Guangzhou – A 24-week course of treatment with the antisense oligonucleotide bepirovirsen achieved a functional cure of hepatitis B in one out of every five patients in two Phase 3 trials. This significantly surpassed the efficacy of current therapies using nucleoside or nucleotide analogs (NAs). The manufacturer presented the results in February...
An unpublished drug for hepatitis B allows some patients to stop treatment without showing signs of the dangerous liver virus, which is known as a “functional cure,” researchers reported.
Guangzhou – A 24-week course of treatment with the antisense oligonucleotide bepirovirsen achieved a functional cure of hepatitis B in one out of every five patients in two Phase 3 trials. This significantly surpassed the efficacy of current therapies using nucleoside or nucleotide analogs (NAs). The manufacturer presented the results in February...